Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 13/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CCR6 | P51684 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.56 |
| ▸ | TLR4 | O00206 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | ABL2 | P42684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366122 | 1.00 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL6910818 | 0.89 | FBP1 (0.78) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL6910815 | 0.89 | FBP1 (0.78) | FBP1EGFRALDH1A1LMNAMAPT | |
| (2-Nitrovinyl)Benzene SCHEMBL28961549 | 0.80 | FBP1 (0.73) | FBP1EGFRALDH1A1LMNAMAPT | |
| Hexamethylbenzene SCHEMBL29275075 | 0.79 | FBP1 (0.84) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL7412213 | 0.78 | FBP1 (0.67) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL421633 | 0.78 | FBP1 (0.64) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL2077031 | 0.78 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL102630 | 0.78 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL1681205 | 0.78 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115073350-B | Preparation method of eremophilone | 苏州富士莱医药股份有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-115073350-A | Preparation method of erexib | 苏州富士莱医药股份有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-106117113-A | Polysubstituted carbazole, derivant and synthetic method thereof | 湘潭大学 | 2016-11-16 | — | — | CN | claimed |
| EP-2982368-A1 | Small molecule compounds displacing focal adhesion core components | Universität Konstanz (DE) | 2016-02-10 | — | — | EP | claimed |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-03-17 | — | — | US | disclosed |
| EP-3964501-B1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | PASTEUR INSTITUT (FR) | 2024-09-04 | — | — | EP | disclosed |
| CN-118420514-A | Method for synthesizing 3- (2-nitro-1-aryl) -1H-indole derivative by using cyclopentadienyl titanium/Bronsted acid in synergistic catalysis mode | 宁夏师范学院 | 2024-08-02 | — | — | CN | disclosed |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2024-06-20 | — | — | US | disclosed |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NEUROPN THERAPEUTICS (US) | 2024-06-04 | — | — | US | disclosed |
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2024-03-26 | — | — | US | disclosed |
| CN-115073350-B | Preparation method of eremophilone | 苏州富士莱医药股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-0672646-A1 | Process for producing beta-nitro-enamines and intermediates thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-09-20 | — | — | EP | disclosed |
| US-5243062-A | Muscle relaxants, analgesics, nervous system disorders, nootropics or antidepressants | CIBA-GEIGY CORPORATION (US) | 1993-09-07 | — | — | US | disclosed |
| US-5004826-A | Chemical Intermediates For Muscle Relaxants, Muscle Stimulants, Analgesics, Anticonvulsants, Antidepressants, Nootropics, And Drugs For Reducing Drug Withdrawal Symptoms | CIBA-GEIGY CORPORATION (US) | 1991-04-02 | — | — | US | disclosed |
| EP-0181833-B1 | SUBSTITUTED PROPANE-PHOSPHONOUS ACID COMPOUNDS | CIBA-GEIGY AG (CH) | 1990-05-02 | — | — | EP | disclosed |
| US-4908465-A | Ethyl phenyl-3-nitropropyl(diethoxymethyl)phosphinate derivatives | CIBA-GEIGY CORPORATION (US) | 1990-03-13 | — | — | US | disclosed |
| US-4772738-A | MUSCLE RELAXANTS, ANALGESICS, ANTICONVULSANTS, ANTIDEPRESSANT | CIBA-GEIGY CORPORATION (US) | 1988-09-20 | — | — | US | disclosed |
| US-4656298-A | MUSCLE RELAXANTS, STIMULANTS, ANALGESICS, ANTICONVULSANTS, ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1987-04-07 | — | — | US | disclosed |
| US-4442264-A | UNSATURATED AROMATIC NITRO OR CHLORINE COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | NISCH, HLCS, CYP3A5 | FBP1 1893/4885EGFR 3915/4885ALDH1A1 972/4885 |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, HLCS, LANCL1 | FBP1 1407/4885EGFR 3403/4885ALDH1A1 659/4885 |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, MRPL21, CRY1 | FBP1 794/4885EGFR 3591/4885ALDH1A1 1484/4885 |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | FBP1 1893/4885EGFR 3915/4885ALDH1A1 972/4885 |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, HPGDS | FBP1 2599/4885EGFR 4349/4885ALDH1A1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.